Skip to content

Henrik Green

Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine, Linköping University, Linköping, Sweden.

2 papers in the library · 6 citations · publishing 2025-2026

Papers

Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples.

Basic & clinical pharmacology & toxicology February 1, 2025 Magnus A B Axelsson, Hanna Lövgren, Robert Kronstrand et al. 6 citations

New psychoactive substances (NPS) are a health hazard due to unpredictable toxicity and unknown prevalence. Analyzing 34,183 oral fluid samples from 9,468 psychiatric and addiction care patients in a Swedish region during 2019–2020, 58 different NPS were detected in 481 samples from 201 patients, totaling 618 findings. NPS use was more common in males and patients aged 25 or older. Ketamine use was associated with most NPS classes except cannabinoids; fentanyl, methadone, tapentadol, and clonazepam also correlated with multiple NPS classes. More traditional drugs of abuse correlated with sedative/hypnotic NPS, suggesting broader use. Mitragynine correlated negatively with other NPS but positively with opioid abstinence remedies buprenorphine, loperamide, and tapentadol, indicating its use for opioid withdrawal.

Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam

Archives of Toxicology May 20, 2026 Caitlyn Norman, Dean Acreman, Meera Bissram et al.

Ethylbromazolam, a new designer benzodiazepine, has emerged in Canada, the UK, Australia, and Germany, with increasing detections since November 2024 and a concurrent decrease in bromazolam detections, likely due to bromazolam's international control on December 3, 2024. Other designer benzodiazepines like desalkylgidazepam and clobromazolam have also increased. In vitro patch clamp assays show ethylbromazolam has similar activity at the GABA-A receptor as bromazolam, with EC50 values of 10.1 nM and 15.2 nM respectively, indicating comparable pharmacological activity and potential harm. Ongoing market monitoring is recommended.